Piper Jaffray Maintains a 'Buy' on Anadys Pharmaceuticals (ANDS), Adds To The Alpha List
More News related to ANDS
- Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Piper Jaffray & Co. maintains a 'Buy' on Anadys Pharmaceuticals (Nasdaq: ANDS), Adds stock to the Alpha List.
Piper analyst says, "We are adding ANDS to the Piper Jaffray Alpha List ahead of value driving data at the European Association for the Study of the Liver meeting (EASL) later this month and a significant partnership by mid year...Our $9 target is based on a proj. enterprise value of $281 million for ANA598 by applying our standard 5x multiple to 2015 projected sales of $640 million discounted back at 50% due to the early stage of the program."
Anadys Pharmaceuticals, Inc., is a biopharmaceutical company focused to develop medicines in the areas of hepatitis C and oncology.
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
